Diabetes News and Research

Latest Diabetes News and Research

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

A statewide Ohio program significantly reduced the monthly rate of inappropriately scheduled births before 39 weeks gestation, helping to avoid expensive neonatal intensive care unit admissions and decrease the risk of infant deaths, according to two studies by the Ohio Perinatal Quality Collaborative recently published in the American Journal of Obstetrics & Gynecology.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Consuming higher amounts of omega-3 fatty acids does not appear to lower heart disease risk for women with type 1 diabetes, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

Medco Health Solutions, BIG direkt gesund execute agreement for advanced pharmacy-driven solutions

Medco Health Solutions and BIG direkt gesund today announced that they have executed an agreement for an innovative portfolio of advanced pharmacy-driven solutions, which upon expressed patient consent, is designed to leverage innovative technologies for improving patient outcomes, adherence, and lowering overall healthcare costs. BIG direkt gesund, a German sick fund that provides health insurance coverage for about 400,000 beneficiaries nationwide, has become the inaugural client for Medco's Advanced Clinical Solutions service offering.

25 Jun 2010

New method to synthesize drug candidates for testing

Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

HHS Secretary to speak about benefits of Affordable Care Act for women

Today, U.S. Secretary of Health and Human Services Secretary Kathleen Sebelius will speak to the National Partnership for Women and Families about how the Affordable Care Act will benefit women.

25 Jun 2010

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

There's been little change over the last three years in how patients rate the care they receive in Saskatchewan hospitals, according to a report released today by the province's Health Quality Council. The report, entitled Quality Insight 2010, presents an overview of aspects of quality of care delivered in hospitals, in the community for people living with certain chronic diseases, and for seniors taking prescription drugs.

25 Jun 2010

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Scientists have shown that a specific virus can interact with a mutation in the host's genes to trigger disease. The observation may help explain why many people with disease risk genes do not actually develop disease.

25 Jun 2010

News roundup: Judge approves $712 million settlement for 9/11 emergency workers' health problems; Missouri ballot measure on health overhaul challenged

A judge approved a $712 million health settlement for thousands of emergency workers who responded after the Sept. 11 attack, in spite of objections from some who complained that the deal was unfair. Some workers who say they got sick working at the Ground Zero site argued Wednesday that the settlement shortchanged those suffering from certain types of diseases. One of the key factors in how much workers get paid under the settlement, approved by U.S. District Judge Alvin Hellerstein, depends on the type of disease the person contracted.

25 Jun 2010

Female patients have fewest complications, shortest hospital stays after gastric bypass surgery: Study

A study of nearly 38,000 patients found Caucasian, Hispanic and female patients have the fewest complications and the shortest hospital stays after laparoscopic gastric bypass surgery, according to University of Nebraska Medical Center researchers who presented their findings today at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

25 Jun 2010

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Neuro Kinetics, Inc., manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it has been awarded a Phase II Small Business Innovation Research grant to further the company's development of a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

25 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

Medco Health Solutions, BIG direkt gesund execute agreement for advanced pharmacy-driven solutions

New method to synthesize drug candidates for testing

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

HHS Secretary to speak about benefits of Affordable Care Act for women

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

News roundup: Judge approves $712 million settlement for 9/11 emergency workers' health problems; Missouri ballot measure on health overhaul challenged

Female patients have fewest complications, shortest hospital stays after gastric bypass surgery: Study

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in